MD Anderson Cancer Center and Biocept, Inc. Study Reveals HER2+ CTCs and DTCs in Patients With HER2- Tumors by Tissue Analysis

Published: Jun 04, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in cancer patients, reported the publication in the journal Cancer Medicine of a paper entitled “Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer” on research performed with collaborators from the University of Texas MD Anderson Cancer Center. One of the key findings of the research was the demonstration that greater than 20% of studied patients classified as HER2- by analysis of their tumors by standard methods were shown to have HER2+ CTCs in blood and/or disseminated tumor cells (DTCs) in bone marrow as determined by fluorescence in situ hybridization (FISH).

Help employers find you! Check out all the jobs and post your resume.

Back to news